#United States #New York #Class Action #Regeneron #fianlimab

Regeneron Pharmaceuticals Faces Class Action Lawsuit

On August 19, 2026, Levi & Korsinsky, LLP announced that investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have reported significant losses due to recent disclosures related to a Class III Fianlimab-Libtayo clinical trial. The lawsuit alleges that the company and its executives misrepresented information during a critical period, leading to a severe decline in stock value.

Significant Stock Decline

The alarming news came after Regeneron’s stock experienced a sharp drop of about 13.95%, falling from $731.77 on April 28, 2026, to $629.68 by May 18, 2026. This loss of $102.09 per share followed the announcement that the Phase III trial for Fianlimab-Libtayo had not reached statistical significance regarding the primary endpoint of progression-free survival (PFS).

According to the allegations, these disclosures corrected previous overly optimistic messaging provided to investors. Levi & Korsinsky claimed that Regeneron concealed certain risks associated with the trial protocol's change on April 29, which expanded the trial's patient population without adequately addressing the implications of a slower accumulation of event data.

Implications for Investors

The lawsuit is noteworthy as it touches on critical aspects of securities law—specifically the necessity of truthful communications with investors. It asserts that misleading statements made during the Class Period may have led shareholders to purchase stock at inflated prices, only to find their investments significantly devalued after the truth was revealed. Investors who purchased shares between August 1, 2025, and May 15, 2026, should determine if they qualify for compensation. Those interested must apply by September 14, 2026.

Analyzing the Timeline

Examining the timeline reveals a systematic pattern of stock price volatility in response to Regeneron's announcements:

• - April 28, 2026: REGN closed at $731.77 before the protocol-changing news was disseminated.
• - April 29, 2026: After the protocol amendment was made public, shares dipped to $686.36, representing about a 6.2% decline on that single trading day.
• - May 15, 2026: The trial's results indicated statistical insignificance regarding PFS improvement, causing further panic among investors.
• - May 18, 2026: REGN shares plummeted further, closing at $629.68, confirming the market's response to these revelations.

Why This Matters

The market's volatility surrounding these disclosures illustrates potential investor harm, which is foundational to the ongoing litigation. Joseph E. Levi, Esq., emphasized that discrepancies between the information provided and the eventual clinical outcomes could serve as compelling evidence of mismanagement and miscommunication to investors.

Common Queries Addressed

What Court is Handling This Case?

The REGN class action lawsuit has been filed in the United States District Court for the Southern District of New York, adhering to the regulations of the Private Securities Litigation Reform Act of 1995.

What if I No Longer Own My Shares?

Investors who bought shares during the relevant time frame and sold at a loss, regardless of their current holdings, may still be eligible to seek compensation.

Do I Need to Attend Court?

Most class members typically do not need to appear in court. If a settlement occurs, they generally fill out a claim form to receive their portion of the recovery.

Global Participation

This class action is inclusive of U.S. exchanges, allowing internationals who purchased stocks to participate, regardless of their country of domicile.

For detailed inquiries or to determine if you are eligible to join the lawsuit, contact Levi & Korsinsky, LLP directly at (212) 363-7500. As they navigate this situation, impacted investors should remain vigilant and proactive in seeking recovery for their losses.

Conclusion

This unfolding scenario surrounding Regeneron Pharmaceuticals stands as a crucial reminder regarding the importance of transparency within the pharmaceutical sector, particularly during clinical trials that could influence investor sentiments and market stability.